Literature DB >> 25393635

From vitamin K antagonists to liver international normalized ratio: a historical journey and critical perspective.

Alexander Gatt1, Dong Chen2, Rajiv K Pruthi2, Patrick S Kamath3, Michael D Leise3, Aneel A Ashrani2, William L Nichols2, Rong He2.   

Abstract

Adoption of international normalized ratio (INR) to harmonize prothrombin time has greatly improved the safety and effectiveness of vitamin K antagonists (VKA) oral anticoagulant therapy. INR is also a major laboratory variable in calculating the widely used Model for End-Stage Liver Disease (MELD) score for liver transplant organ prioritization. However, since the conventional INR (INRVKA) is calibrated specifically for VKA patients, its interlaboratory variation has a significant impact on the accuracy of MELD score. Though still requiring further clinical validation in large numbers of waitlisted patients, the alternative liver INR calibrated by using plasma from liver disease patients instead of VKA patients may harmonize the differences and thus more suitable for MELD score calculation. The objective of this article is to review the history of INR, MELD score, and liver INR, and discuss the challenges and solutions of liver INR implementation. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25393635     DOI: 10.1055/s-0034-1395160

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  2 in total

1.  Cholesterol esterification in plasma as a biomarker for liver function and prediction of mortality.

Authors:  Thorsten Kaiser; Benedict Kinny-Köster; Michael Bartels; Thomas Berg; Markus Scholz; Cornelius Engelmann; Daniel Seehofer; Susen Becker; Uta Ceglarek; Joachim Thiery
Journal:  BMC Gastroenterol       Date:  2017-04-20       Impact factor: 3.067

Review 2.  Hemostatic Testing in Critically Ill Infants and Children.

Authors:  Alison B Nair; Robert I Parker
Journal:  Front Pediatr       Date:  2021-01-08       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.